<DOC>
	<DOCNO>NCT01163396</DOCNO>
	<brief_summary>This single-arm , open-label , multicentre phase II study evaluate safety efficacy combination G.O.N.O . FOLFOXIRI regimen bevacizumab first-line treatment metastatic colorectal cancer .</brief_summary>
	<brief_title>First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm colorectal adenocarcinoma Unresectable measurable metastatic disease ( RECIST criterion ) Male female , age &gt; 18 year ≤ 75 year ECOG Performance Status ( PS ) &lt; 2 age &lt; 71 year ECOG PS = 0 aged 7175 year Life expectancy 3 month Adequate haematological function : ANC ≥ 1.5 x 109/L ; platelet ≥ 100 x 109/L , Hb ≥ 9 g/dL INR ≤ 1.5 aPTT ≤ 1.5 x ULN within 7 day prior start study treatment Adequate liver function : serum bilirubin ≤ 1.5 x ULN ; alkaline phosphatase transaminases ≤ 2.5 x ULN ( case liver metastases &lt; 5 x ULN ) Serum Creatinine ≤ 1.5 x ULN Urine dipstick proteinuria &lt; 2+ . If urine dipstick ≥ 2+ , 24 hour urine must demonstrate ≤ 1 g protein 24 hour Previous adjuvant chemotherapy allow 12 month elapse end adjuvant therapy first relapse At least 6 week prior radiotherapy 4 week surgery Prior palliative chemotherapy Prior treatment bevacizumab Bowel obstruction ( subobstruction ) History inflammatory enteropathy extensive intestinal resection ( &gt; hemicolectomy extensive small intestine resection chronic diarrhea ) Symptomatic peripheral neuropathy &gt; 2 grade NCICCTG criterion Presence history CNS metastasis Active uncontrolled infection Active disseminate intravascular coagulation Major surgical procedure , open biopsy significant traumatic injury within 28 day prior treatment , anticipation need major surgery course study Central Venous Access Device ( CVAD ) chemotherapy administration insert within 2 day prior study treatment start Past current history malignancy colorectal carcinoma , except curatively treat basal squamous cell carcinoma skin cancer situ carcinoma cervix Clinically significant cardiovascular disease , example cerebrovascular accident ( CVA ) ( ≤ 6 month treatment start ) , myocardial infarction ( ≤ 6 month treatment start ) , unstable angina , NYHA ≥ grade 2 chronic heart failure ( CHF ) , uncontrolled arrhythmia Uncontrolled hypertension 24hour urine protein &gt; 1 g dipstick &gt; 2+ History thromboembolic hemorrhagic event within 6 month prior treatment Evidence bleed diathesis coagulopathy Serious , non heal wound/ulcer serious bone fracture No therapeutic anticoagulation antiplatelet agent NSAID antiplatelet activity ( aspirin ≤ 325 mg/day allow ) Pregnancy lactation Fertile woman ( &lt; 2 year last menstruation ) men childbearing potential willing use effective mean contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>